OH Pharma
Products › Metabolism › Retatrutide 20 mg
Retatrutide 10 mg OH PharmaRetatrutide 10 mg OH Pharma – back of vial
Retatrutide 20 mg OH PharmaRetatrutide 20 mg OH Pharma – back of vial
Retatrutide 30 mg OH PharmaRetatrutide 30 mg OH Pharma – back of vial

Swipe to see the other strengths

Metabolism · File 02

Retatrutide 20 mg

Analysis in progress

✓Sterility and endotoxins tested by Nelson Labs (Salt Lake City)

Incretin receptor agonists (GLP-1, GIP, glucagon).

Calculate a dose →

Description

Triple agonist peptide of the GIP, GLP-1 and glucagon receptors, three hormones involved in regulating appetite, blood sugar and energy expenditure.

Studied benefits

  • Substantial weight loss in trials.
  • Lower HbA1c in people with type 2 diabetes.
  • Improvement in knee osteoarthritis pain in some populations with obesity.
  • Improvement in obstructive sleep apnea in the relevant trials.

Results reported in published research; they guarantee no effect and are not an indication for use.

🔬 What the research says
  • Phase 2 trial (NEJM, 2023; 338 adults, 48 weeks): mean weight loss of up to 24.2% at the highest dose, versus about 2% on placebo.
  • Phase 3 trials TRIUMPH‑2 and TRIUMPH‑3 (80 weeks): weight reduction of up to 20.8% and 22.6% depending on the population studied.
⚠️ Warnings and reported side effects
  • Common digestive effects: diarrhea (24–34%), nausea (21–28%), constipation (16–18%), vomiting.
  • Dose-dependent increase in heart rate (phase 2).
  • Up to 13.5% of participants stopped treatment because of adverse effects, versus about 5% on placebo.
  • GLP‑1 agonist class warnings: pancreatitis, gallbladder disorders, thyroid tumours seen in rodents. Not recommended during pregnancy.

Consult a healthcare professional before any use. If an adverse effect occurs, stop use and see a doctor.

Certificate of analysis coming soon

This product's lot is awaiting its laboratory results. The certificate will be published on this page as soon as it is received. Every new lot is sent for analysis before being published here.

Sources

  1. Jastreboff et al., NEJM 2023 — phase 2 trial
  2. Patient Care — TRIUMPH‑2 and ‑3 results (July 2026)
  3. Health Canada — advisory on unauthorized injectable peptides (April 2026)

For educational purposes only. This information summarizes published studies and is neither a recommendation for use nor medical advice.

← Back to products